Canada Gazette, Part I, Volume 153, Number 47: GOVERNMENT NOTICES

November 23, 2019

DEPARTMENT OF HEALTH

HAZARDOUS MATERIALS INFORMATION REVIEW ACT

Decisions, undertakings and orders on claims for exemption

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of the decisions of the screening officer respecting each claim for exemption and the relevant safety data sheet (SDS) and (where applicable) the label listed below.

In accordance with section 20 of the Hazardous Materials Information Review Act, a claimant or any affected party, as defined, may appeal a decision or order of a screening officer. An affected party may also appeal an undertaking in respect of which a notice has been published in the Canada Gazette. To initiate the appeal process, a Statement of Appeal (Form 1) as prescribed by the Hazardous Materials Information Review Act Appeal Board Procedures Regulations must be completed and delivered, along with the fee prescribed by section 12 of the Hazardous Materials Information Review Regulations, within 45 days of the publication of this notice in the Canada Gazette, Part I, to the Chief Appeals Officer at the following address: Workplace Hazardous Materials Bureau, 269 Laurier Avenue West, 8th Floor, 4908B, Ottawa, Ontario K1A 0K9.

Véronique Lalonde
Chief Screening Officer

On February 11, 2015, the Hazardous Products Act (HPA) was amended, and the Controlled Products Regulations (CPR) and the Ingredient Disclosure List were repealed and replaced with the new Hazardous Products Regulations (HPR). The revised legislation (HPA/HPR) is referred to as WHMIS 2015.

All claims for exemption in this publication were filed and evaluated in accordance with the provisions of WHMIS 2015.

A Notice of Filing was published in Part I of the Canada Gazette and there were no written representations from affected parties with respect to any of the claims for exemption and related SDSs or labels mentioned below.

Each of the claims for exemption listed in the table below was found to be valid except for those for Registry Numbers (RNs) 11223 and 12158, which were found to be invalid. The screening officer reached this decision after reviewing the information in support of the claim, having regard exclusively to the criteria found in section 3 of the Hazardous Materials Information Review Regulations.

RN

Claimant

Product Identifier

Date of Decision

9614

TBF Environmental Technology Inc.

TergoSol

2019-06-20

9615

TBF Environmental Technology Inc.

ZemaSol

2019-02-20

9707

Multi-Chem Production Chemicals Co.

MC MX 1-1521

2019-08-06

9826

Lamberti Canada, Incorporated

HI 232C

2019-08-22

9960

BYK USA Inc.

Anti-Terra-U 80

2019-07-31

9961

BYK USA Inc.

BYK-W 980

2019-08-14

9988

Atotech Canada Ltd.

VITROCOAT GI S-0

2019-07-26

10026

Innospec Fuel Specialties LLC

OGI-7625

2019-08-20

10071

Sialco Materials Ltd.

EBR-2430

2019-08-12

10156

Nalco Canada ULC

NALCO® 61950

2019-08-28

10354

Nalco Canada ULC

NALBRITE™ 62513

2019-08-13

10372

BWA Water Additives US LLC

DP3562

2019-08-26

10419

Secure Energy Services Inc.

K-ForMAX Seal

2019-08-15

10441

Nalco Canada ULC

Froth Pro™ 708

2019-08-21

10448

Nalco Canada ULC

MIN# H12C1

2019-08-26

10614

Baker Hughes Canada Company

ARKLEAR™ 4074 WATER CLARIFIER

2019-08-19

11177

Ingevity Corporation

EVOTHERM® M1

2019-09-06

11223

ArrMaz Products, L.P.

DUSTROL® 3010-R

2019-09-26

11225

ArrMaz Products, L.P.

CustoFloat™ 7080

2019-08-16

11263

Ingevity Corporation

INDULIN® QTS (Canada)

2019-08-12

11264

Ingevity Corporation

INDULIN® SBT

2019-08-12

11270

BYK USA Inc.

DISPERBYK-106

2019-07-31

11506

BYK USA Inc.

BYK-W 9010

2019-08-02

11612

Halliburton Group Canada

FDP-M1087-13

2019-08-22

11828

Nalco Canada ULC

NALCO® TX16868

2019-07-31

11838

Halliburton Group Canada

G-SPERSE

2019-07-04

11840

Halliburton Group Canada

HC-2

2019-08-22

11882

Atotech Canada Ltd.

Master Remover 4001

2019-08-21

11884

Atotech Canada Ltd.

Master Remover 7000

2019-08-28

11909

Halliburton Group Canada

LCA-1

2019-07-05

12085

Integrity Bio-Chem

IronFix LP

2019-08-27

12090

Chemours Canada Company

Capstone™ ST-100HS

2019-07-10

12092

Chemours Canada Company

Capstone™ FS-65

2019-07-10

12097

Legend Brands

UnDuzIt Unleashed

2019-08-30

12145

Henkel Canada Corporation

LOCTITE NS 5540

2019-08-27

12158

Clean Harbours

Paratene S1

2019-08-27

12255

Baker Hughes Canada Company

FORSA™ SCW600 SCALE INHIBITOR

2019-08-19

The subject of the claim on which the screening officer issued a decision for the following claims is different from the subject of the claim that was published in the Notice of Filing.

RN

Notice of Filing Publication Date

Original Subject of the Claim

Revised Subject of the Claim

9826

2016-03-26

C.i. and C. of one ingredient

C.i. and C. of one ingredient
C. of one ingredient

11828

2018-01-13

C.i. of two ingredients
C. of three ingredients

C.i. of two ingredients

12085

2018-07-09

C.i. and C. of two ingredients

C.i. and C. of one ingredient

Note: C.i. = chemical identity and C. = concentration

In all cases where the SDS or the label was determined not to be in compliance with the relevant legislation, pursuant to subsection 16.1(1) of the Hazardous Materials Information Review Act, the claimant was given 30 days to provide the screening officer with a signed undertaking accompanied by the SDS or the label amended as necessary.

Non-compliances that fall outside the scope of what is required to be published in the Canada Gazette are referred to as “administrative non-compliances.”

Please refer to Health Canada’s List of Active Claims for Exemption for a description of “administrative non-compliances” and their associated corrective measures.

CLAIMS FOR WHICH THE SCREENING OFFICER WAS SATISFIED THAT THE CLAIMANT HAD TAKEN THE MEASURES SET OUT IN THE UNDERTAKING

Pursuant to paragraph 18(1)(b) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that has been disclosed on the relevant SDS or label in compliance with an undertaking and the date on which the notice referred to in subsection 16.1(3) of the Act was issued.

RN: 9614
Date of compliance undertaking: 2019-09-13

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose an adequate emergency telephone number.
  2. Disclose the product’s boiling range.
  3. Disclose the calculated product inhalation ATE value of 21.4 mg/L (0% unknown).
  4. Correct the disclosure of misleading information regarding the LC50 value for the product.
RN: 9615
Date of compliance undertaking: 2019-09-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose an adequate emergency telephone number.
  2. Disclose the additional hazard classification of “Skin Sensitizer — Category 1B”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the product’s boiling range.
  5. Disclose that the confidential ingredient “aryl halide” has been shown to be a skin sensitizer.
RN: 9826
Date of compliance undertaking: 2019-09-17

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose an adequate emergency telephone number.
  2. Disclose the additional hazard classifications of “Reproductive Toxicity — Category 2”, “Specific Target Organ Toxicity — Single Exposure (oral and dermal: eye) — Category 1”, and “Specific Target Organ Toxicity — Single Exposure (inhalation) — Category 3 (Narcotic Effect)”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the percent of unknown toxicity for the calculated product ATE values.
  5. Disclose the applicable common names and synonyms for the ingredient “methanol”.
  6. Disclose appropriate first aid measures in the case of skin contact.
  7. Disclose appropriate engineering controls.
  8. Disclose “chromium trioxide” and “nitric acid” as incompatible materials.
  9. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  10. Disclose that the ingredient “methanol” has been shown to cause reproductive toxicity effects.
  11. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  12. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
RN: 9960
Date of compliance undertaking: 2019-10-09

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional hazard classifications of “Acute Toxicity (Oral) — Category 4”, “Acute Toxicity (Dermal) — Category 3”, “Acute Toxicity (Inhalation) — Category 3”, and “Eye Irritation — Category 2”.
  2. Disclose the symbol and/or name of symbol for “Skull and Crossbones” on the SDS.
  3. Disclose the signal word “Danger”.
  4. Disclose the percent of unknown toxicity of “80%” for the calculated product oral, dermal and inhalation ATE values.
  5. Disclose the information elements concerning the additional hazard and precautionary statements.
  6. Disclose the applicable common names and synonyms for the ingredient “2-butoxyethanol”.
  7. Disclose the most important symptoms and effects, whether acute or delayed.
  8. Correct the disclosure of misleading information regarding engineering controls.
  9. Disclose the product’s flammability.
  10. Disclose “static discharge, shock or vibration” as conditions to avoid.
  11. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  12. Disclose the calculated product oral ATE value of 530 mg/kg and calculated product dermal ATE value of 400 mg/kg.
  13. Correct the disclosure of misleading information regarding the LC50 value for the ingredient “2-butoxyethanol”.
RN: 9961
Date of compliance undertaking: 2019-10-09

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional hazard classifications of “Acute Toxicity (Oral) — Category 4”, “Acute Toxicity (Dermal) — Category 3”, “Acute Toxicity (Inhalation) — Category 3”, and “Eye Irritation — Category 2”.
  2. Disclose the symbol and/or name of symbol for “Skull and Crossbones” on the SDS.
  3. Disclose the signal word “Danger”.
  4. Disclose the percent of unknown toxicity of “80%” for the calculated product oral, dermal and inhalation ATE values, respectively.
  5. Disclose the information elements concerning the additional hazard and precautionary statements.
  6. Disclose the applicable common names and synonyms for the ingredient “2-butoxyethanol”.
  7. Disclose the most important symptoms and effects, whether acute or delayed.
  8. Correct the disclosure of misleading information regarding engineering controls.
  9. Disclose the product’s flammability.
  10. Disclose “static discharge, shock or vibration” as conditions to avoid.
  11. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  12. Disclose the calculated product oral ATE value of 530 mg/kg and calculated product dermal ATE value of 400 mg/kg.
  13. Correct the disclosure of misleading information regarding the LC50 value for the ingredient “2-butoxyethanol”.
RN: 10026
Date of compliance undertaking: 2019-09-16

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the Canadian initial supplier identifier.
  2. Disclose the additional hazard classification of “Specific Target Organ Toxicity — Single Exposure — Category 1 (stomach, lungs, kidneys and central nervous system)”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the symbol and/or name of the symbol for “Health hazard” on the SDS.
  5. Disclose the target organs for the classification “Specific Target Organ Toxicity — Single Exposure — Category 1 (stomach, lungs, kidneys and central nervous system)”.
  6. Disclose the applicable common names and synonyms for the ingredient “isopropanol”.
  7. Correct the disclosure of misleading information regarding first aid measures.
  8. Correct the disclosure of misleading information regarding personal protective equipment.
  9. Correct the disclosure of misleading information regarding accidental release measures.
  10. Disclose the applicable precautions for safe handling and conditions for safe storage.
  11. Disclose an adequate product odour.
  12. Disclose “chromium trioxide (oxidizer)” as an incompatible material.
  13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  14. Disclose the likely route of exposure in section 11, “Toxicological information”.
  15. Disclose the calculated product oral ATE value of 6 800 mg/kg (25% unknown).
RN: 10071
Date of compliance undertaking: 2019-09-12

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”.
  2. Remove CANUTEC’s emergency telephone number.
  3. Disclose the additional hazard classification of “Skin Sensitizer — Category 1B”.
  4. Disclose the information elements concerning the additional hazard and precautionary statements.
  5. Disclose “Other hazards” on the SDS.
  6. Disclose the symptoms and effects, whether acute or delayed.
  7. Correct the disclosure of misleading information regarding suitable extinguishing media.
  8. Disclose an adequate product odour.
  9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  10. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
RN: 10156
Date of compliance undertaking: 2019-09-26

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose an adequate emergency telephone number.
  2. Disclose the additional hazard classifications of “Skin Irritation — Category 2” and “Serious Eye Damage — Category 1”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the symbols and/or name of symbols for “Corrosion” and “Exclamation mark” on the SDS.
  5. Disclose the signal word “Danger”.
  6. Disclose the applicable common names and synonyms for the ingredient “hydrotreated light distillate”.
  7. Correct the disclosure of misleading information regarding first aid measures.
  8. Disclose the appropriate first aid measures.
  9. Disclose emergency procedures to follow in case of accidental release.
  10. Correct the disclosure of misleading information regarding accidental release measures.
  11. Disclose an adequate product odour.
  12. Disclose the product’s reactivity.
  13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  14. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 10354
Date of compliance undertaking: 2019-09-20

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose an adequate emergency telephone number.
  3. Disclose the applicable common names and synonyms for the ingredient “citric acid”.
  4. Correct the disclosure of misleading information regarding “the most important symptoms and effects, whether acute or delayed” under section 4, “First-aid measures”.
  5. Disclose the product’s melting point and freezing point.
  6. Disclose the product’s reactivity.
  7. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  8. Disclose the calculated product oral ATE value of 29 000 mg/kg (0% unknown).
  9. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 10372
Date of compliance undertaking: 2019-09-05

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the symbol and/or name of the symbol for “Exclamation mark” on the SDS.
  2. Disclose “Other hazards” on the SDS.
  3. Disclose the product’s flammability.
  4. Disclose the appropriate information under section 9, “Physical and chemical properties”.
  5. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  6. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  7. Correct the disclosure of misleading information regarding inhalation.
RN: 10419
Date of compliance undertaking: 2019-09-05

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose an adequate emergency telephone number.
  4. Disclose the additional hazard classification of “Skin Corrosion — Category 1”.
  5. Disclose the information elements concerning the additional hazard and precautionary statements.
  6. Disclose the hazardous combustion products.
  7. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  8. Disclose the calculated product oral ATE value of 4 400 mg/kg (0% unknown).
RN: 10441
Date of compliance undertaking: 2019-09-26

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the disclosure of misleading information regarding first aid measures.
  3. Disclose a description of necessary first aid measures.
  4. Correct the disclosure of misleading cross-referencing between SDS sections.
  5. Disclose the missing physical data.
  6. Disclose the product’s melting point and freezing point.
  7. Disclose an adequate product odour.
  8. Disclose the product’s reactivity.
  9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  10. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 10448
Date of compliance undertaking: 2019-09-26

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose the applicable common names and synonyms for the ingredient “hydrotreated light distillate”.
  3. Correct the disclosure of misleading information regarding first aid measures.
  4. Correct the disclosure of misleading information regarding accidental release measures.
  5. Disclose an adequate product odour.
  6. Disclose the product’s melting point and freezing point.
  7. Disclose the product’s reactivity.
  8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  9. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  10. Disclose the calculated product oral ATE value of 29 000 mg/kg (33.2% unknown).
RN: 10614
Date of compliance undertaking: 2019-09-10

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”.
  2. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  3. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  4. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 11177
Date of compliance undertaking: 2019-10-08

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose “Other hazards” on the SDS.
  3. Disclose the necessary protective equipment.
  4. Correct the disclosure of misleading information regarding accidental release measures.
  5. Correct the disclosure of misleading information regarding handling and storage.
  6. Correct the disclosure of misleading information regarding exposure controls/personal protection.
  7. Disclose the melting point of < 25 °C, and the boiling point of > 300 °C.
  8. Disclose “oxides of carbon” and “oxides of nitrogen” as hazardous decomposition products.
  9. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 11270
Date of compliance undertaking: 2019-08-28

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose the symptoms and effects, whether acute or delayed.
  4. Correct the disclosure of misleading information regarding first aid measures in case of skin contact.
  5. Disclose the product’s flammability, in the case of solids and gases.
  6. Disclose the product’s viscosity.
  7. Disclose “static discharge, shock or vibration” as conditions to avoid.
  8. Disclose the symptoms related to physical, chemical and toxicological characteristics.
  9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  10. Disclose the calculated product oral ATE value of 3 500 mg/kg and calculated dermal ATE value of 2 740 mg/kg.
  11. Correct the disclosure of misleading information regarding the LD50 (rabbit, dermal) value of 2 740 mg/kg for the ingredient “phosphoric acid (residual)”.
  12. Disclose that this product has been shown to be corrosive to the skin/a skin irritant.
  13. Disclose that this product has been shown to be corrosive to the eyes/an eye irritant.
  14. Correct the disclosure of misleading information regarding respiratory or skin sensitization.
RN: 11506
Date of compliance undertaking: 2019-08-28

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Correct the disclosure of misleading information regarding first aid measures in case of skin contact.
  3. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
  4. Disclose an adequate product pH.
  5. Disclose an adequate product flammability, in the case of solids and gases.
  6. Disclose “take measures to prevent the build up of electrostatic charge” as a condition to avoid.
  7. Disclose the symptoms related to physical, chemical and toxicological characteristics.
  8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  9. Disclose the calculated product oral ATE value of 3 500 mg/kg and calculated dermal ATE value of 2 740 mg/kg.
  10. Correct the disclosure of misleading information regarding the LD50 (rabbit, dermal) of 2 740 mg/kg value for the confidential ingredient “phosphoric acid (residual)”.
RN: 11828
Date of compliance undertaking: 2019-09-05

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Remove CANUTEC’s emergency telephone number.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Disclose the additional hazard classifications of “Skin Corrosion — Category 1” and “Serious Eye Damage — Category 1”.
  4. Disclose the symbol and/or name of the symbol for “Corrosion” on the SDS.
  5. Disclose the signal word “Danger”.
  6. Disclose the applicable common names and synonyms for the ingredient “benzotriazole”.
  7. Disclose the applicable information for “the most important symptoms and effects, whether acute or delayed” under section 4, “First-aid measures”.
  8. Disclose emergency procedures to follow in case of accidental release.
  9. Disclose the applicable information for “personal precautions, protective equipment and emergency procedures” under section 6, “Accidental release measures”.
  10. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
  11. Disclose an adequate product odour.
  12. Disclose the product’s reactivity.
  13. Disclose the delayed and immediate effects, as well as the chronic effects from short-term and long-term exposure.
  14. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 12085
Date of compliance undertaking: 2019-09-13

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the Canadian initial supplier identifier.
  2. Disclose the additional hazard classifications of “Skin Corrosion — Category 1” and “Serious Eye Damage — Category 1”.
  3. Disclose the symbol and/or name of the symbol for “Corrosion” on the SDS.
  4. Disclose the signal word “Danger”.
  5. Disclose the information elements concerning the additional hazard and precautionary statements.
  6. Disclose “Other hazards” on the SDS.
  7. Disclose a statement equivalent to “IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing”.
  8. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
  9. Disclose the hazardous combustion products.
  10. Disclose emergency procedures to follow in case of accidental release.
  11. Disclose conditions for incompatibilities of the hazardous product.
  12. Disclose an accurate product colour.
  13. Disclose an adequate product odour.
  14. Disclose a numerical value of the vapour pressure and vapour density.
  15. Correct the disclosure of misleading information regarding symptoms related to the physical, chemical and toxicological characteristics.
  16. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 12090
Date of compliance undertaking: 2019-09-11

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the applicable information for “personal precautions, protective equipment and emergency procedures” under section 6, “Accidental release measures”.
  3. Correct the disclosure of misleading information regarding the precautionary statement in section 7.
  4. Disclose an accurate product colour.
  5. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  6. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 12092
Date of compliance undertaking: 2019-09-11

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the information elements concerning additional hazard and precautionary statements.
  3. Correct the disclosure of misleading information with respect to personal protective equipment for first aid measures.
  4. Disclose the applicable information for “personal precautions, protective equipment and emergency procedures” under section 6, “Accidental release measures”.
  5. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
  6. Correct the disclosure of misleading information regarding the precautionary statement in section 7.
  7. Correct the disclosure of misleading information regarding respiratory protective equipment.
  8. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 12097
Date of compliance undertaking: 2019-10-08

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose the applicable information for “the most important symptoms and effects” under section 4, “First-aid measures”.
  3. Disclose the applicable information under section 4, “First-aid measures”.
  4. Disclose personal precautions and emergency procedures to follow in case of accidental release.
  5. Correct the disclosure of misleading cross-referencing between SDS sections.
  6. Disclose the applicable information for “advice on safe handling” under section 7, “Handling and storage”.
  7. Disclose the applicable information under section 8, “Exposure controls/personal protection”.
  8. Disclose an adequate product odour.
  9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  10. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the ingredient “polyethylene glycol, > C5 ether”.
  11. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  12. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
RN: 12145
Date of compliance undertaking: 2019-10-03

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose an adequate emergency telephone number.
  3. Disclose the percent of unknown toxicity for the product oral ATE value.
  4. Disclose “Other hazards” on the SDS.
  5. Disclose the applicable common names and synonyms for the ingredients “quartz (SiO2), < 1% respirable” and “alkanes, C9-12-iso-”.
  6. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
  7. Disclose the immediate medical attention/special treatment needed for exposure to the product.
  8. Disclose an adequate product odour.
  9. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  10. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 12255
Date of compliance undertaking: 2019-09-10

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Disclose the information elements concerning the additional hazard and precautionary statements.
  3. Disclose “Other hazards” on the SDS.
  4. Disclose the applicable common names and synonyms for the ingredient “sodium bisulfite”.
  5. Correct the disclosure of misleading information regarding handling and storage.
  6. Correct the disclosure of misleading information regarding exposure controls/personal protection.
  7. Disclose an adequate product odour.
  8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  9. Disclose the calculated product oral ATE value of 23 810 mg/kg.
  10. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
  11. Disclose the likely routes of exposure in section 11, “Toxicological information”.

CLAIMS FOR WHICH THE SCREENING OFFICER ORDERED THE CLAIMANT TO COMPLY WITH THE APPLICABLE DISCLOSURE REQUIREMENTS

In the case of the following claims, either the claimant did not supply the screening officer with a signed undertaking or the screening officer was not satisfied that the claimant had taken the measures set out in the undertaking in the manner and within the period specified in it. Pursuant to subsection 17(1) of the Hazardous Materials Information Review Act, the screening officer ordered the claimant to comply with the requirements of the relevant legislation within 30 days from the expiry of the appeal period, except that the information in respect of which the claim for exemption was made does not have to be disclosed, and to provide a copy of the amended SDS to the screening officer within 30 days of expiry of the appeal period.

Pursuant to paragraph 18(1)(a) of the Hazardous Materials Information Review Act, the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on the SDS reviewed by the screening officer and the date of the order.

RN: 9707
Date of order: 2019-09-10

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose the additional hazard classifications of “Specific Target Organ Toxicity — Single Exposure — Category 3 (narcotic effects)” and “Flammable Liquids — Category 1”.
  3. Disclose the percent of unknown toxicity for the calculated product oral, dermal, and inhalation ATE values.
  4. Disclose the applicable common names and synonyms for the ingredient “methanol”.
  5. Correct the disclosure of misleading information regarding the first aid measures.
  6. Correct the disclosure of misleading information regarding the important symptoms and effects, whether acute or delayed.
  7. Correct the disclosure of misleading information regarding suitable extinguishing media.
  8. Disclose the protective equipment for firefighters.
  9. Disclose the hazardous combustion products.
  10. Correct the disclosure of misleading information regarding protective equipment.
  11. Disclose an accurate product colour.
  12. Disclose an adequate product odour.
  13. Disclose “static discharge” as a condition to avoid.
  14. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  15. Disclose the calculated product oral ATE value of 6 400 mg/kg.
RN: 9988
Date of order: 2019-09-06

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the information elements concerning the additional hazard and precautionary statements.
  2. Disclose an adequate emergency telephone number.
  3. Disclose the additional hazard classification of “Eye Irritation — Category 2B”.
  4. Correct the disclosure of misleading information regarding potential acute health effects.
  5. Correct the disclosure of misleading information regarding the firefighting measures.
  6. Disclose an accurate product colour.
  7. Disclose the physical properties of the product.
  8. Disclose “oxides of carbon” as a hazardous decomposition product.
  9. Disclose the calculated product oral ATE value of 2 490 mg/kg and calculated dermal ATE value of 3 770 mg kg.
  10. Disclose that the confidential ingredient “aliphatic hydroxy ether” has been shown to be an irritant to the eyes.
  11. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
RN: 11225
Date of order: 2019-09-19

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose an adequate emergency telephone number.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Correct the disclosure of misleading information regarding potential skin contact.
  5. Disclose the hazardous combustion products.
  6. Correct the disclosure of misleading information regarding personal protective equipment.
  7. Disclose an adequate product odour.
  8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  9. Disclose the calculated product ATE values.
RN: 11263
Date of order: 2019-09-18

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Disclose “Other hazards” on the SDS.
  3. Disclose the necessary protective equipment in section 6, “Accidental release measures”.
  4. Correct the disclosure of misleading information regarding section 7, “Handling and storage”.
  5. Correct the disclosure of misleading information regarding section 8, “Exposure controls/Personal protection”.
  6. Disclose the melting point of <25 oC, and the boiling point of >300 °C.
  7. Disclose the likely routes of exposure in section 11, “Toxicological information”.
RN: 11264
Date of order: 2019-09-18

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional hazard classification of “Specific Target Organ Toxicity — Single Exposure — Category 1 (kidneys, central nervous system)”.
  2. Disclose the signal word “Danger”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose “Other hazards” on the SDS.
  5. Disclose the necessary protective equipment in section 6, “Accidental release measures”.
  6. Correct the disclosure of misleading information regarding section 6, “Accidental release measures”.
  7. Correct the misleading information regarding section 7, “Handling and storage”.
  8. Disclose a statement equivalent to “Wash … thoroughly after handling” in section 7.
  9. Correct the disclosure of misleading information regarding section 8, “Exposure controls/Personal protection”.
RN: 11612
Date of order: 2019-09-26

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Disclose the additional hazard classifications of “Reproductive Toxicity — Category 2” and “Specific Target Organ Toxicity — Single Exposure — Category 1 (central nervous system and kidneys)”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the applicable common names and synonyms for the ingredient “ethylene glycol”.
  5. Correct the disclosure of misleading information regarding “the most important symptoms and effects” under section 4, “First-aid measures”.
  6. Correct the disclosure of misleading information regarding first aid measures.
  7. Disclose information on the special protective equipment and precautions for firefighters.
  8. Disclose specific hazards arising from the hazardous product.
  9. Disclose an ACGIH TLV–TWA of 25 ppm (vapour fraction), an ACGIH TLV–STEL of 50 ppm (vapour fraction), and an ACGIH–STEL of 10 mg/m3 (aerosol only) 1H, as exposure limits for the ingredient “ethylene glycol”.
  10. Disclose an accurate product colour/physical state.
  11. Disclose an adequate product odour.
  12. Disclose “chromium trioxide (oxidizer), perchloric acid (strong acid/oxidizer), potassium permanganate (oxidizer) and sodium hypochlorite (oxidizer)” as incompatible materials.
  13. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  14. Disclose the calculated product oral ATE value of 100 000 mg/kg (5% unknown) and calculated dermal ATE value of 48 000 mg/kg (13% unknown).
  15. Correct the disclosure of misleading information regarding the LD50 (rabbit, dermal) value for the confidential ingredient “ethoxylated alcohols #1”.
RN: 11838
Date of order: 2019-09-06

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  2. Disclose statements conveying the relevant precautionary information in section 4 of the SDS.
  3. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
  4. Disclose information on the special protective equipment and precautions for firefighters.
  5. Disclose the applicable information for “personal precautions, protective equipment and emergency procedures” under section 6, “Accidental release measures”.
  6. Disclose statements conveying the relevant precautionary information in section 7 of the SDS.
  7. Disclose an adequate product colour.
  8. Disclose an adequate product odour.
  9. Disclose “ingestion” as an additional likely route of exposure.
  10. Disclose symptoms related to the physical, chemical and toxicological characteristics.
  11. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  12. Disclose the calculated product ATE values.
RN: 11840
Date of order: 2019-09-24

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Correct the precautionary statements to select the appropriate phrases when a slash is present.
  3. Disclose the Canadian initial supplier identifier.
  4. Correct the disclosure of misleading information regarding the most important symptoms and effects, whether acute or delayed.
  5. Disclose personal precautions and emergency procedures to follow in case of accidental release.
  6. Disclose an adequate product odour.
  7. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  8. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  9. Disclose the calculated product oral ATE value of 10 870 mg/kg.
  10. Correct the disclosure of misleading information regarding the LD50 (rat, oral) value for the confidential ingredient “inner salt of alkyl amines”.
RN: 11882
Date of order: 2019-09-24

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 4, “First-aid measures”.
  2. Disclose the additional hazard classification of “Reproductive Toxicity — Category 2”.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose the symbol and/or name of the symbol for “Health hazard” on the SDS.
  5. Disclose the percent of unknown toxicity for the calculated product oral and inhalation ATE values.
  6. Disclose the applicable common names and synonyms for the ingredient “diethylene glycol monobutyl ether”.
  7. Disclose the additional ingredient “benzene, C10-16-alkyl derivatives”.
  8. Correct the disclosure of misleading information regarding personal protective equipment in case of accidental release.
  9. Correct the disclosure of misleading cross-referencing between SDS sections.
  10. Disclose incompatibilities of the hazardous product.
  11. Disclose an adequate product odour.
  12. Disclose the product’s relative density.
  13. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  14. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  15. Disclose that the ingredient “benzene, C10-16-alkyl derivatives” has been shown to cause reproductive toxicity effects.
RN: 11884
Date of order: 2019-10-03

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Disclose an adequate emergency telephone number.
  3. Disclose the additional hazard classification of “Eye Irritation — Category 2”.
  4. Disclose the information elements concerning the additional hazard and precautionary statements.
  5. Disclose the percent of unknown toxicity of “2%” for the calculated product oral ATE value.
  6. Disclose the additional ingredient “alcohols, C11-15-secondary, ethoxylated”.
  7. Disclose the applicable common names and synonyms for the ingredients “diethylene glycol monobutyl ether” and “alcohols, C11-15-secondary, ethoxylated”.
  8. Correct the disclosure of misleading cross-referencing between SDS sections.
  9. Disclose incompatibilities of the hazardous product.
  10. Disclose an adequate product odour.
  11. Disclose the product’s relative density.
  12. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.
  13. Disclose the likely routes of exposure in section 11, “Toxicological information”.
  14. Disclose the symptoms related to the physical, chemical and toxicological characteristics.
RN: 11909
Date of order: 2019-10-07

The claimant had been advised to correct administrative non-compliances in the SDS (or label) and had been further advised to amend the SDS (or label) as indicated below.

  1. Disclose the additional information elements in section 7, “Handling and storage”, and section 4, “First-aid measures”.
  2. Disclose the Canadian initial supplier identifier.
  3. Disclose the information elements concerning the additional hazard and precautionary statements.
  4. Disclose “carbon dioxide, dry chemical, foam” as a suitable extinguishing media.
  5. Disclose “oxides of carbon” as additional hazardous combustion product.
  6. Disclose information on the precautions for firefighters.
  7. Disclose the flash point of 66–67 °C, solubility of 1.5 mg/100 mL at 20 °C, and the partition coefficient (n-octanol/water) of 3.4-8.
  8. Disclose an adequate product odour.
  9. Disclose a sufficient description of the delayed and immediate effects, and chronic effects from short-term and long-term exposure.

CLAIMS FOR WHICH THE SCREENING OFFICER ISSUED THE DECISION THAT THE CLAIM FOR EXEMPTION WAS EITHER PARTIALLY VALID OR INVALID

In the case of the following claims, the screening officer issued the decision that the claim for exemption was invalid.

Pursuant to section 18 of the Hazardous Materials Information Review Act (HMIRA), the Chief Screening Officer hereby gives notice of information that the screening officer ordered to be disclosed on an SDS or a label pursuant to subsection 16(1) and information that has been disclosed on the relevant SDS or label in compliance with an undertaking, and the dates on which the orders and notices referred to in subsection 16.1(3) of the Act were issued.

RN: 11223
Date of decision: 2019-09-26

The claimant had been advised to amend the SDS (or label) to remove the link to the HMIRA registry number.

RN: 12158
Date of decision: 2019-08-27

The claimant had been advised to amend the SDS (or label) to remove the link to the HMIRA registry number.